What is MindMaze Therapeutics Holding 3-Year RORE %?
MindMaze Therapeutics HoldingRLFTY 11 3-Year RORE % is 0.00 as of Dec. 2025. GuruFocus rates RLFTY with a GF Score™ of 11/100. The stock has 2 warning signs investors should review. Among 1,291 Biotechnology companies, MindMaze Therapeutics Holding ranks worse than 77459.26% on this metric.
Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments.
MindMaze Therapeutics Holding does not have enough data to calculate 3-Year RORE %.
Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.
There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 3-year period is chosen.
Be Aware
Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.
MindMaze Therapeutics Holding 3-Year RORE % Related Terms
MindMaze Therapeutics Holding 3-Year RORE % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MindMaze Therapeutics Holding 3-Year RORE % Chart
MindMaze Therapeutics Holding Annual Data
Trend
Dec24
Dec25
3-Year RORE %
0.00
0.00
MindMaze Therapeutics Holding Semi-Annual Data
Dec24
Dec25
3-Year RORE %
0.00
0.00
RLFTY vs VRTX, REGN, ALNY: 3-Year RORE % Comparison
For the Biotechnology subindustry, MindMaze Therapeutics Holding's 3-Year RORE %, along with its competitors' market caps and 3-Year RORE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
MindMaze Therapeutics Holding 3-Year RORE % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, MindMaze Therapeutics Holding's 3-Year RORE % distribution charts can be found below:
* The bar in red indicates where MindMaze Therapeutics Holding's 3-Year RORE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of 3-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Dec. 2025 and 3-year before.
MindMaze Therapeutics Holding (RLFTY) has a 3-Year RORE % of 0.00 as of Dec. 2025. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on MindMaze Therapeutics Holding and its competitors. According to the industry distribution chart, MindMaze Therapeutics Holding ranks #999999 out of 1291 companies in the Biotechnology industry.
Is MindMaze Therapeutics Holding's 3-Year RORE % too high?
MindMaze Therapeutics Holding's current 3-Year RORE % is 0.00. Based on the distribution chart, MindMaze Therapeutics Holding ranks #999999 out of 1291 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, MindMaze Therapeutics Holding has a GF Score™ of 11/100, reflecting its overall financial health beyond just this single metric.
How does MindMaze Therapeutics Holding's 3-Year RORE % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, MindMaze Therapeutics Holding ranks #999999 out of 1291 companies for 3-Year RORE %. This places MindMaze Therapeutics Holding in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year RORE % for a Biotechnology company?
A good 3-Year RORE % depends on the Biotechnology industry context. However, 3-Year RORE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year RORE % mean?
A high 3-Year RORE % can signal that a stock is expensive relative to its fundamentals. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on MindMaze Therapeutics Holding and its competitors. MindMaze Therapeutics Holding's current 3-Year RORE % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MindMaze Therapeutics Holding stock overvalued right now?
MindMaze Therapeutics Holding (RLFTY) has a current 3-Year RORE % of 0.00. The current 3-Year RORE % is 0.00. MindMaze Therapeutics Holding's overall GF Score™ is 11/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year RORE % calculated?
3-Year RORE % is calculated from a company's financial statements. For MindMaze Therapeutics Holding (RLFTY), the current 3-Year RORE % is 0.00 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
MindMaze Therapeutics Holding Business Description
MindMaze Therapeutics Holding SA is a Swiss-based, commercial-stage biopharmaceutical and neurotechnology company. The company develops and commercializes digital treatments for neurological diseases and brain disorders. Its technology platform integrates software, sensors, and telehealth, and its solutions are used in clinical and home settings internationally. The company has developed evidence-based, next-generation neurotherapeutics that provide evidence-based motor and cognitive treatments to redefine clinical outcomes in patients with neurological disease and brain disorders. The company also manages Relief's existing portfolio of clinical and commercial biopharmaceutical assets focused on rare dermatological, metabolic, and respiratory diseases.
11GF Score
Get the complete analysis for RLFTY
3-Year RORE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
RLFTY has been successfully added to your 